184 related articles for article (PubMed ID: 36399073)
1. IL-2-based approaches to Treg enhancement.
Harris F; Berdugo YA; Tree T
Clin Exp Immunol; 2023 Mar; 211(2):149-163. PubMed ID: 36399073
[TBL] [Abstract][Full Text] [Related]
2. Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.
Kosmaczewska A
Int J Mol Sci; 2014 Oct; 15(10):18574-92. PubMed ID: 25322151
[TBL] [Abstract][Full Text] [Related]
3. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
4. How GRAIL controls Treg function to maintain self-tolerance.
Fathman CG; Yip L; Gómez-Martín D; Yu M; Seroogy CM; Hurt CR; Lin JT; Jenks JA; Nadeau KC; Soares L
Front Immunol; 2022; 13():1046631. PubMed ID: 36569931
[TBL] [Abstract][Full Text] [Related]
5. The role of FOXP3
Mohr A; Atif M; Balderas R; Gorochov G; Miyara M
Clin Exp Immunol; 2019 Jul; 197(1):24-35. PubMed ID: 30830965
[TBL] [Abstract][Full Text] [Related]
6. Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity.
Zhou P
Cytokine Growth Factor Rev; 2022 Oct; 67():80-88. PubMed ID: 35803833
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.
Tsyklauri O; Chadimova T; Niederlova V; Kovarova J; Michalik J; Malatova I; Janusova S; Ivashchenko O; Rossez H; Drobek A; Vecerova H; Galati V; Kovar M; Stepanek O
Elife; 2023 Jan; 12():. PubMed ID: 36705564
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases.
Tahvildari M; Dana R
J Immunol; 2019 Dec; 203(11):2749-2755. PubMed ID: 31740549
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
10. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
Terry LV; Oo YH
Front Immunol; 2020; 11():565518. PubMed ID: 33072105
[TBL] [Abstract][Full Text] [Related]
11. Treg Enhancing Therapies to Treat Autoimmune Diseases.
Eggenhuizen PJ; Ng BH; Ooi JD
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977677
[TBL] [Abstract][Full Text] [Related]
12. "IL-2 immunotherapy for targeting regulatory T cells in autoimmunity".
Lykhopiy V; Malviya V; Humblet-Baron S; Schlenner SM
Genes Immun; 2023 Oct; 24(5):248-262. PubMed ID: 37741949
[TBL] [Abstract][Full Text] [Related]
13. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis.
Buitrago-Molina LE; Pietrek J; Noyan F; Schlue J; Manns MP; Wedemeyer H; Hardtke-Wolenski M; Jaeckel E
J Autoimmun; 2021 Feb; 117():102591. PubMed ID: 33387980
[TBL] [Abstract][Full Text] [Related]
14. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
15. Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.
Ballesteros-Tato A
Immunotherapy; 2014; 6(11):1207-20. PubMed ID: 25496335
[TBL] [Abstract][Full Text] [Related]
16. Fine tuning subsets of CD4
Zhao Z; Zhang X; Su L; Xu L; Zheng Y; Sun J
Int Immunopharmacol; 2018 Mar; 56():269-276. PubMed ID: 29414661
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.
Graßhoff H; Comdühr S; Monne LR; Müller A; Lamprecht P; Riemekasten G; Humrich JY
Front Immunol; 2021; 12():648408. PubMed ID: 33868284
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases.
Xu L; Song X; Su L; Zheng Y; Li R; Sun J
Int Immunopharmacol; 2019 Jul; 72():322-329. PubMed ID: 31005777
[TBL] [Abstract][Full Text] [Related]
19. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
[TBL] [Abstract][Full Text] [Related]
20. Cytokine Signaling in the Development and Homeostasis of Regulatory T cells.
Toomer KH; Malek TR
Cold Spring Harb Perspect Biol; 2018 Mar; 10(3):. PubMed ID: 28620098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
